A global collaboration between Tampere University (Finland), the Massachusetts General Research Institute and the Harvard Stem Cell Institute (both MA, USA) has found a new drug combination that is effective against T-cell acute lymphoblastic leukemia – otherwise known as T-ALL.
T-ALL is a form of ALL (the most common childhood cancer) that has a poor prognosis and develops from early T lineage cells. Relapsed T-ALL, in particular, desperately requires innovative new combination treatments due to the fact that individual drugs tend to rapidly lose their efficacy for leukemia.
The research team from Tampere University previously discovered that the general tyrosine kinase inhibitor, dasatinib, was effective in one-third of patient samples that were tested. In this new study, the researchers used an ex vivo high-throughput screening platform to search for drugs that would work effectively in combination with dasatinib and enhance its therapeutic impact…
Get the full article and findings from the study on our sister site Oncology Central.
[ui-btn url=”https://www.oncology-central.com/fresh-hope-for-relapsed-t-cell-acute-lymphoblastic-leukemia/” text=”Read on” target=”_blank”][/ui-btn]
The post Fresh hope for relapsed T-cell acute lymphoblastic leukemia appeared first on BioTechniques.
Powered by WPeMatico